BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Moodys
Express Scripts
Accenture
Chubb
Healthtrust
US Department of Justice
Deloitte
US Army
AstraZeneca

Generated: January 18, 2018

DrugPatentWatch Database Preview

Sandoz Company Profile

« Back to Dashboard

What is the competitive landscape for SANDOZ, and what generic alternatives to SANDOZ drugs are available?

SANDOZ has six hundred and ninety-one approved drugs.

There are two US patents protecting SANDOZ drugs on SANDOZ drugs in the past three years. There are twenty-eight tentative approvals on SANDOZ drugs.

There are twenty patent family members on SANDOZ drugs in eighteen countries and three hundred and thirty supplementary protection certificates in thirteen countries.

Summary for Sandoz
International Patents:20
US Patents:2
Tradenames:386
Ingredients:359
NDAs:691

Drugs and US Patents for Sandoz

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz CEFPROZIL cefprozil TABLET;ORAL 065235-002 Nov 14, 2005 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz CETIRIZINE HYDROCHLORIDE ALLERGY cetirizine hydrochloride TABLET;ORAL 077946-002 Dec 27, 2007 OTC No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz TEMAZEPAM temazepam CAPSULE;ORAL 071427-001 Jan 12, 1988 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz CANDESARTAN CILEXETIL candesartan cilexetil TABLET;ORAL 078702-004 May 3, 2013 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz MECLOFENAMATE SODIUM meclofenamate sodium CAPSULE;ORAL 072263-001 Nov 29, 1988 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz LISINOPRIL lisinopril TABLET;ORAL 075903-006 Jul 1, 2002 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz DESIPRAMINE HYDROCHLORIDE desipramine hydrochloride TABLET;ORAL 072104-001 Jun 20, 1988 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz PROPOXYPHENE HYDROCHLORIDE propoxyphene hydrochloride CAPSULE;ORAL 084014-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz Inc ATORVASTATIN CALCIUM atorvastatin calcium TABLET;ORAL 077575-001 May 29, 2012 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Sandoz ENOXAPARIN SODIUM (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 077857-003 Jul 23, 2010 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for SANDOZ drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 6/3/2015

Non-Orange Book US Patents for Sandoz

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,261,547 Gelling ophthalmic compositions containing xanthan gum ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Sandoz Drugs

Supplementary Protection Certificates for Sandoz Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB09/024 United Kingdom ➤ Subscribe PRODUCT NAME: COMBINATION COMPRISING ALISKIREN, AS THE FREE BASE OR AS A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: CH 5893501 20081028; CH 5893502 20081028; CH 5893503 20081028; CH 5893504 20081028; UK EU/1/08/491/006 20090116; UK EU/1/08/491/002 20090116; UK EU/1/08/491/003 20090116; UK EU/1/08/491/004 20090116; UK EU/1/08/491/005 20090116; UK EU/1/08/491/007 20090116; UK EU/1/08/491/080 20090116; UK EU/1/08/491/074 20090116; UK EU/1/08/491/075 20090116; UK EU/1/08/491/076 20090116; UK EU/1/08/491/077 20090116; UK EU/1/08/491/078 20090116; UK EU/1/08/491/079 20090116; UK EU/1/08/491/068 20090116; UK EU/1/08/4
90007 Netherlands ➤ Subscribe PRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT; REGISTRATION NO/DATE: EU/1/98/089/001-EU/1/98/089/010 19981211
C/GB96/004 United Kingdom ➤ Subscribe PRODUCT NAME: ANASTROZOLE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT; REGISTRATION NO/DATE: UK 12619/0106 19950811
/1998 Austria ➤ Subscribe PRODUCT NAME: RIZATRIPTAN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE RIZATRIPTANBENZOAT; NAT. REGISTRATION NO/DATE: 1-22636 - 1-22639 19980709; FIRST REGISTRATION: NL 21815 - 21818 19980211
30/2006 Austria ➤ Subscribe PRODUCT NAME: AMLODIPIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SÄUREADDITIONSALZ DESSELBEN IN KOMBINATION MIT ATORVASTATIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ DESSELBEN
C/GB01/025 United Kingdom ➤ Subscribe PRODUCT NAME: LINEZOLID; REGISTERED: UK PL 00032/0259 20010105; UK PL 00032/0260 20010105; UK PL 00032/0261 20010105; UK PL 00032/0262 20010105
00499 Netherlands ➤ Subscribe PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114
70044 Netherlands ➤ Subscribe PRODUCT NAME: CANDESARTAN, DESGENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF VAN DE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYLESTE R, IN HET BIJZONDER CILEXETILI CANDESARTANAS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 21703 - RVG 21706 19971013; FIRST REGISTRATION: GB PL 15661/0001 - PL 15661/0004 19970429
C0013 Belgium ➤ Subscribe PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
/2012 Austria ➤ Subscribe PRODUCT NAME: KOMBINATIONSPRODUKT VON SAXAGLIPTIN UND METFORMIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON, BEINHALTEND DIE HYDROCHLORIDSALZE VON SAXAGLIPTIN UND METFORMIN; REGISTRATION NO/DATE: EU/1/11/731/001-EU/1/11/731/012 20111124
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Colorcon
Cipla
Queensland Health
Fuji
McKinsey
US Army
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot